WAVE Life Sciences (NASDAQ:WVE) Releases Earnings Results, Misses Estimates By $0.03 EPS

WAVE Life Sciences (NASDAQ:WVE) released its earnings results on Thursday. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.03), FiscalAI reports. The business had revenue of $2.27 million for the quarter, compared to the consensus estimate of $6.53 million. WAVE Life Sciences had a negative net margin of 255.70% and a negative return on equity of 56.76%.

Here are the key takeaways from WAVE Life Sciences’ conference call:

• WVE-007 obesity development advanced into Phase IIa with dosing underway in patients with higher BMI and comorbidities. The company is also planning combination-with-incretin and post-incretin maintenance studies this year, targeting fat loss with muscle preservation and potentially once- or twice-yearly dosing.
• WVE-006 produced data the company says support treatment of both lung and liver manifestations of AATD with infrequent subcutaneous dosing. The FDA granted a meeting expected later this summer to discuss a potential accelerated-approval pathway, while data from the 600 mg cohort are expected in the second half of 2026.
• Wave remains on track to submit a CTA for WVE-008 in PNPLA3 liver disease in 2026. The RNA-editing program aims to restore functional protein rather than silence the target, with preclinical data showing more than 50% editing and reduced lipid accumulation versus siRNA.
• The company is exploring partnerships for its DMD candidate WVE-N531 before filing an NDA, citing an evolving regulatory and commercial landscape. Management said it continues to believe in the program but will reassess filing plans based on regulatory developments and partnership progress.
• Second-quarter revenue fell to $2.3 million from $8.7 million a year earlier, while the net loss widened to $69.4 million from $50.5 million as R&D and G&A spending increased. Wave ended the quarter with $490.6 million in cash and expects funding into Q3 2028, excluding potential future GSK milestone payments.

WAVE Life Sciences Stock Down 6.0%

NASDAQ:WVE traded down $0.34 during mid-day trading on Friday, reaching $5.42. The company’s stock had a trading volume of 220,665 shares, compared to its average volume of 3,882,721. The firm has a market capitalization of $1.04 billion, a PE ratio of -5.17 and a beta of -1.29. The stock has a fifty day moving average of $5.99 and a 200-day moving average of $9.00. WAVE Life Sciences has a 1 year low of $5.02 and a 1 year high of $21.73.

Analysts Set New Price Targets

A number of research analysts have issued reports on WVE shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of WAVE Life Sciences in a research note on Friday, July 17th. Zacks Research upgraded shares of WAVE Life Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. New Street Research set a $13.00 target price on WAVE Life Sciences in a report on Thursday, June 11th. HC Wainwright reissued a “buy” rating on shares of WAVE Life Sciences in a report on Thursday, June 11th. Finally, Citigroup cut their target price on shares of WAVE Life Sciences from $30.00 to $24.00 and set a “buy” rating for the company in a research report on Monday, May 4th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $25.06.

Institutional Trading of WAVE Life Sciences

Institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in WAVE Life Sciences by 9.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 57,349 shares of the company’s stock valued at $463,000 after acquiring an additional 4,957 shares during the last quarter. Goldman Sachs Group Inc. increased its position in WAVE Life Sciences by 3.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 557,644 shares of the company’s stock valued at $4,506,000 after buying an additional 20,624 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of WAVE Life Sciences by 22.5% during the second quarter. Rhumbline Advisers now owns 162,599 shares of the company’s stock valued at $1,057,000 after acquiring an additional 29,899 shares in the last quarter. Prudential Financial Inc. purchased a new position in shares of WAVE Life Sciences in the 2nd quarter valued at approximately $80,000. Finally, Norges Bank acquired a new stake in WAVE Life Sciences in the 2nd quarter worth approximately $650,000. 89.73% of the stock is currently owned by institutional investors.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.